Modality
mRNA
MOA
GLP-1/GIP
Target
CD19
Pathway
Tau
CMLMelanoma
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
Aug 2017
→ Nov 2030
Phase 3Current
NCT06469779
2,412 pts·CML
2024-03→2030-11·Active
NCT06233511
1,280 pts·Melanoma
2017-08→2028-06·Active
NCT05967588
193 pts·Melanoma
2020-07→2030-09·Recruiting
3,885 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2028-06-042.2y awayPh3 Readout· Melanoma
2030-09-224.5y awayPh3 Readout· Melanoma
2030-11-104.6y awayPh3 Readout· CML
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Active
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2028-06-04 · 2.2y away
Melanoma
Ph3 Readout
2030-09-22 · 4.5y away
Melanoma
Ph3 Readout
2030-11-10 · 4.6y away
CML
RecruitingActive|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06469779 | Phase 3 | CML | Active | 2412 | EASI-75 |
| NCT06233511 | Phase 3 | Melanoma | Active | 1280 | NT-proBNP |
| NCT05967588 | Phase 3 | Melanoma | Recruiting | 193 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| VYG-2926 | Voyager | NDA/BLA | CD19 |